Key Points
- Tpg Gp A, Llc sold 250,000 shares of Sionna on January 22 at an average price of $40.00 for $10.0 million, trimming its stake by 3.71% to 6,494,962 shares.
- Shares opened at $42.60 with a one‑year range of $7.26–$45.00; the company has a market cap of about $1.90 billion and a negative PE ratio (‑8.75).
- Analyst sentiment is mixed but leaning positive—MarketBeat shows an average rating of "Moderate Buy" with an average target price of $45.43, ranging from sell to strong‑buy.
Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) major shareholder Tpg Gp A, Llc sold 250,000 shares of the company's stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $40.00, for a total transaction of $10,000,000.00. Following the transaction, the insider owned 6,494,962 shares in the company, valued at $259,798,480. This represents a 3.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
Sionna Therapeutics Price Performance
Shares of SION opened at $42.60 on Tuesday. Sionna Therapeutics, Inc. has a one year low of $7.26 and a one year high of $45.00. The company has a market cap of $1.90 billion and a PE ratio of -8.75. The stock has a 50-day moving average of $41.26 and a 200-day moving average of $31.71.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.06.
Wall Street Analysts Forecast Growth
A number of analysts have commented on the stock. Royal Bank Of Canada restated an "underperform" rating and set a $24.00 price target on shares of Sionna Therapeutics in a research note on Monday, December 1st. Lifesci Capital assumed coverage on shares of Sionna Therapeutics in a research report on Tuesday, December 23rd. They set an "outperform" rating and a $60.00 target price for the company. BTIG Research reaffirmed a "buy" rating and issued a $58.00 price target on shares of Sionna Therapeutics in a research report on Wednesday, January 14th. Wall Street Zen upgraded Sionna Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, December 13th. Finally, Raymond James Financial reissued a "strong-buy" rating and issued a $53.00 price objective on shares of Sionna Therapeutics in a research note on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $45.43.
Check Out Our Latest Stock Analysis on SION
Hedge Funds Weigh In On Sionna Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Bank of America Corp DE increased its position in shares of Sionna Therapeutics by 8.8% during the third quarter. Bank of America Corp DE now owns 6,541 shares of the company's stock valued at $192,000 after acquiring an additional 529 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Sionna Therapeutics by 35.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company's stock worth $70,000 after buying an additional 619 shares during the last quarter. Russell Investments Group Ltd. bought a new position in Sionna Therapeutics during the third quarter valued at about $30,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Sionna Therapeutics during the fourth quarter worth about $89,000. Finally, Police & Firemen s Retirement System of New Jersey bought a new stake in Sionna Therapeutics in the second quarter worth about $45,000.
About Sionna Therapeutics
(
Get Free Report)
Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.
At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
